Plus Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights

– Received FDA Orphan Drug and Fast Track designations for novel glioblastoma radiotherapy –

Go here to read the rest:
Plus Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights

Related Posts